Oxcarbazepine in the treatment of acute affective episodes in bipolar disorder: efficacy and acceptability
Referencias
Additional references
Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R. Re‐evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. Journal of Affective Disordorders 2000;59(Suppl 1):5‐30.
Alderson P, Green S, Higgins JP. The Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]. Chichester, UK: John Wiley & Sons Ltd, 2004.
Altman D, Bland M. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
American Psychiatric Association. Diagnostic and Statistics Manual of mental disorders (DSM‐IV). 4th Edition. Washington, DC: American Psychiatric Association, 1994.
Beydoun A, Kutluay E. Oxcarbazepine. Expert Opinion on Pharmacotherapy 2002;3(1):59‐71.
Bowden CL. Role of newer medications for bipolar disorder. Journal of Clinical Psychopharmacology 1996;16(2 Suppl 1):48‐55.
Calabresi P, De Murtas M, Stefani A, Pisani A, Sancesario G, Mercuri NB, et al. Action of GP 47779, the active metabolite of oxcarbazepine on the corticostriatal system. I . Modulation of corticostriatal synaptic transmission. Epilepsia 1995;36(10):990‐6.
De Leon OA. Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder. Harvard Review of Psychiatry 2001;9(5):209‐22.
Dietrich DE, Kropp S, Emrich HM. Oxcarbazepine in affective and schizoaffective disorders. Pharmacopsychiatry 2001;34(6):242‐50.
Emrich HM, Dose M, Von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepne in patients with affective disorder. Journal of Affective Disorders 1985;8(3):243‐50.
Gelder MG, Lopez Ibor JJ, Andreasen NC. New Oxford Textbook of Psychiatry. Oxford: Oxford University Press, 2003.
Ghaemi SN, Ko JY, Katzow JJ. Oxcarbazepine treatment of refractory bipolar disorder: a retrospective chart review. Bipolar Disorders 2002;4(1):70‐4.
Hummel B, Walden J, Stampfer R, Dittmann S, Amann B, Sterr A, et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on‐off design. Bipolar disorders 2002;4(6):412‐7.
Isojarvi V, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994;35(6):1217‐20.
Keck PE, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. Journal of Clinical Psychiatry 2000;61(Suppl 4):33‐8.
Kleinman L, Lowin A, Flood E, Gandhi G, Edgell E, Revicki D. Costs of bipolar disorder. Pharmacoeconomics 2003;21(9):601‐22.
Muller AA, Stoll KD. Carbamazepine and oxcarbazepine in the treatment of manic syndromes: studies in Germany. In: Emrich HM, Okuma T, Muller AA editor(s). Anticonvulsants in affective disorders. Amsterdam: Elsevier Science Ltd, 1984:139‐147.
Munoz RA. Oxcarbazepine for the treatment of bipolar disorder. American Psychiatric Association, 2002, Philadelphia. 2002.
Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: global burden of disease study. Lancet 1997;349(9063):1436‐42.
Oxman A. Preparing and maintaining systematic reviews.. Cochrane Collaboration Handbook. Vol. section VI, updated 14th July, Oxford: Update Software, 1995.
Medical Economics Co. Physicians' Desk Reference. 5th Edition. Montvale, NJ: Medical Economics Co, 2001.
Schatzberg AF, Nemeroff CB. The American Psychiatric Publishing textbook of psychopharmacology. Arlington, VA: American Psychiatric Publishing Inc, 2004.
Schmutz MF, Gentsch C, McLean MJ, Olpe HR. Oxcarbazepine, preclinical anticonvulsant profile and putative mechanism of action. Epilepsia 1994;35(Suppl 5):47‐50.
Stahl SM. Essential psychopharmacology of depression and bipolar disorder. Cambridge: Cambridge University Press, 2000.
World Health Organisation. The ICD‐10 Classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines. Geneva: World Health Organisation, 1992.
